Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
Follow ZYBT
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+1 more quarter Free account |
1.17 | 2.75 | 6.65 | 7.42 |
Receivables |
11.45 | 10.10 | 6.88 | 2.96 | |
Inventory |
8.97 | 7.98 | 7.48 | 5.60 | |
Other current assets |
2.16 | — | — | 3.67 | |
Total current assets |
26.11 | 24.33 | 28.12 | 19.65 | |
Property, Plant, Equpment (Net) |
49.03 | 50.24 | 34.44 | 52.71 | |
Goodwill and Intangible Assets (Total) |
3.39 | 3.12 | 3.23 | 7.83 | |
Long Term Assets (Tax, Deferred) |
— | — | 2.28 | — | |
Long-term assets (Other) |
2.60 | 2.56 | 2.37 | 1.00 | |
Total non-current assets |
55.02 | 58.53 | 42.32 | 61.54 | |
Total Assets |
67.10 | 67.58 | 70.44 | 62.41 | |
Accounts Payable |
5.73 | 5.89 | 5.98 | 6.30 | |
Accrued Expenses |
0.22 | 0.77 | 0.53 | 0.50 | |
Current Part of Debt |
12.03 | 11.18 | 11.32 | 9.41 | |
Current Part of Capital Lease |
— | 0.00 | — | 0.00 | |
Current Part of Taxes to Pay |
0.53 | 0.28 | 0.30 | 0.34 | |
Other current liabilities |
0.41 | 0.50 | 0.70 | 0.68 | |
Total current liabilities |
18.91 | 18.62 | 18.82 | 17.23 | |
Long Term Debt (Total) |
— | 0.66 | 0.66 | 1.27 | |
Non-current Revenue (Deferred) |
— | 0.00 | — | 0.02 | |
Minority Interests |
— | 0.00 | — | 0.00 | |
Non-current Liabilities (Other) |
0.05 | — | — | — | |
Total non-current liabilities |
0.05 | 0.66 | 0.66 | 1.28 | |
Total liabilities |
18.96 | 19.28 | 19.48 | 18.56 | |
Additional Paid In Capital |
27.95 | 27.83 | 33.61 | 34.43 | |
Preferred Stock (Total) |
— | 0.00 | — | 0.00 | |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | |
Retained Earnings |
6.49 | 6.60 | 3.70 | (3.10) | |
Treasury Stock |
— | 0.00 | — | 0.00 | |
Shareholders Equity (Other) |
13.69 | 13.87 | 4.56 | 12.53 | |
Common Equity (Total) |
48.13 | 48.30 | 50.97 | 43.85 | |
Shareholders Equity (Total) |
48.13 | 48.30 | 50.97 | 43.85 | |
Shareholders Equity and Liabilities (Total) |
67.10 | 67.58 | 70.44 | 62.41 | |
Shares (Common) |
45.67 | — | 47.39 | — | |
Shareholders Equity (Tangible) |
44.75 | 45.18 | 47.73 | 36.03 | |
Net Debt |
10.85 | 9.10 | 5.32 | 3.26 | |
Total Debt |
12.03 | 11.84 | 11.97 | 10.68 |